Cell Replacement Therapy in Parkinson's Disease-History of Development and Prospects for Use in Clinical Practice

被引:1
作者
Katolikova, N., V [1 ,2 ]
Malashicheva, A. B. [2 ,3 ]
Gainetdinov, R. R. [1 ,4 ]
机构
[1] St Petersburg State Univ, Inst Translat Biomed, St Petersburg 199034, Russia
[2] Russian Acad Sci, Inst Cytol, St Petersburg 194064, Russia
[3] Minist Hlth Russian Federat, Almazov Natl Med Res Ctr, St Petersburg 197341, Russia
[4] St Petersburg State Univ, Pirogov Clin High Med Technol, St Petersburg 199034, Russia
基金
俄罗斯基础研究基金会; 英国医学研究理事会;
关键词
Parkinson’ s disease; cell replacement therapy; embryonic stem cells; induced pluripotent stem cells; cell differentiation; neuronal progenitors; EMBRYONIC STEM-CELLS; IN-VITRO DIFFERENTIATION; DOPAMINE NEURONS; NEURAL PROGENITORS; FUNCTIONAL-NEURONS; SPEMANN ORGANIZER; DOUBLE-BLIND; RAT MODEL; ES CELLS; TRANSPLANTATION;
D O I
10.1134/S0026893320060060
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Abstract- Parkinson's disease is a widespread neurodegenerative disease, which is characterized by the death of dopaminergic neurons in the substantia nigra of the midbrain. Clinically, the disease is manifested by tremor, bradykinesia, muscle rigidity, and other motor and non-motor symptoms that ultimately lead to disability. To date, there are only symptomatic treatment options for Parkinson's disease; therefore, the search for new approaches is one of the most important directions of therapy for this disease. In the 1970's the idea of using cell replacement therapy based on the local nature and specificity of damage to a particular type of neuron in Parkinson's disease originated. The selection of the source of cells, the method and place of introduction, indications for this operation, and peculiarities of patient management have been in development for a long time. The efficiency of cell replacement therapy has been confirmed by a number of studies on animal models. Clinical trials have already begun and several more are planned soon. This review describes the main prerequisites for the use of cell replacement therapy in Parkinson's disease, the stages of development of this method, and clinical trials that have started in the last few years.
引用
收藏
页码:827 / 839
页数:13
相关论文
共 80 条
[51]   The future of stem cell therapies for Parkinson disease [J].
Parmar, Malin ;
Grealish, Shane ;
Henchcliffe, Claire .
NATURE REVIEWS NEUROSCIENCE, 2020, 21 (02) :103-115
[52]   BRAIN GRAFTS REDUCE MOTOR ABNORMALITIES PRODUCED BY DESTRUCTION OF NIGROSTRIATAL DOPAMINE SYSTEM [J].
PERLOW, MJ ;
FREED, WJ ;
HOFFER, BJ ;
SEIGER, A ;
OLSON, L ;
WYATT, RJ .
SCIENCE, 1979, 204 (4393) :643-647
[53]   Dopamine release from nigral transplants visualized in vivo in a Parkinson's patient [J].
Piccini, P ;
Brooks, DJ ;
Björklund, A ;
Gunn, RN ;
Grasby, PM ;
Rimoldi, O ;
Brundin, P ;
Hagell, P ;
Rehncrona, S ;
Widner, H ;
Lindvall, O .
NATURE NEUROSCIENCE, 1999, 2 (12) :1137-1140
[54]   Culture development for human embryonic stem cell propagation: molecular aspects and challenges [J].
Rao, BM ;
Zandstra, PW .
CURRENT OPINION IN BIOTECHNOLOGY, 2005, 16 (05) :568-576
[55]   Neural progenitors from human embryonic stem cells [J].
Reubinoff, BE ;
Itsykson, P ;
Turetsky, T ;
Pera, MF ;
Reinhartz, E ;
Itzik, A ;
Ben-Hur, T .
NATURE BIOTECHNOLOGY, 2001, 19 (12) :1134-1140
[56]   Embryonic stem cell lines from human blastocysts: somatic differentiation in vitro [J].
Reubinoff, BE ;
Pera, MF ;
Fong, CY ;
Trounson, A ;
Bongso, A .
NATURE BIOTECHNOLOGY, 2000, 18 (04) :399-404
[57]   Patient-specific stem cell lines derived from human parthenogenetic blastocysts [J].
Revazova, E. S. ;
Turovets, N. A. ;
Kochetkova, O. D. ;
Kindarova, L. B. ;
Kuzmichev, L. N. ;
Janus, J. D. ;
Pryzhkova, My. .
CLONING AND STEM CELLS, 2007, 9 (03) :432-449
[58]   XENOPUS CHORDIN - A NOVEL DORSALIZING FACTOR-ACTIVATED BY ORGANIZER-SPECIFIC HOMEOBOX GENES [J].
SASAI, Y ;
LU, B ;
STEINBEISSER, H ;
GEISSERT, D ;
GONT, LK ;
DEROBERTIS, EM .
CELL, 1994, 79 (05) :779-790
[59]   Nurr1 is essential for the induction of the dopaminergic phenotype and the survival of ventral mesencephalic late dopaminergic precursor neurons [J].
Saucedo-Cardenas, O ;
Quintana-Hau, JD ;
Le, WD ;
Smidt, MP ;
Cox, JJ ;
DeMayo, F ;
Burbach, JPH ;
Conneely, OM .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1998, 95 (07) :4013-4018
[60]   Personalized iPSC-Derived Dopamine Progenitor Cells for Parkinson's Disease [J].
Schweitzer, Jeffrey S. ;
Song, Bin ;
Herrington, Todd M. ;
Park, Tae-Yoon ;
Lee, Nayeon ;
Ko, Sanghyeok ;
Jeon, Jeha ;
Cha, Young ;
Kim, Kyungsang ;
Li, Quanzheng ;
Henchcliffe, Claire ;
Kaplitt, Michael ;
Neff, Carolyn ;
Rapalino, Otto ;
Seo, Hyemyung ;
Lee, In-Hee ;
Kim, Jisun ;
Kim, Taewoo ;
Petsko, Gregory A. ;
Ritz, Jerome ;
Cohen, Bruce M. ;
Kong, Sek-Won ;
Leblanc, Pierre ;
Carter, Bob S. ;
Kim, Kwang-Soo .
NEW ENGLAND JOURNAL OF MEDICINE, 2020, 382 (20) :1926-1932